Navigation Links
Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Date:11/11/2008

Study highlights:

- Researchers present promising results from dose-ranging study of new oral anti-coagulant in patients with acute coronary syndrome.

- Phase III trial slated to begin in December.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- Researchers reported on a study of a new oral anti-clotting agent -- rivaroxaban -- designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

"The goal of any early study is to find the right dose and the right way to give the drug, and we met that objective," said C. Michael Gibson, M.S., M.D., principal investigator, chief of clinical research at the Beth Israel Deaconess Medical Center and director of the Thrombolysis in Myocardial Infarction (TIMI) data coordinating center at Brigham and Women's Hospital, Boston, Mass. "We studied four different doses and both once-a-day and twice-a-day dosing schedules for this Factor Xa, (pronounced ten-A) inhibitor."

The Phase II, randomized, placebo-controlled study on 3,491 patients treated at 297 medical centers in 27 countries originally had safety as the primary endpoint, but its design also included efficacy endpoints, he said. The primary efficacy endpoint was a composite of death, heart attack, stroke and severe ischemia revascularization. The secondary endpoint was a composite of death, heart attack or stroke.

Earlier studies had shown the experimental drug rivaroxaban effective at keeping blood clots from forming in the veins during and after major orthopedic surgery. ATLAS ACS-TIMI 46 is the first test of the drug in the arteries -- which face higher pressures than the venous circulation -- and the first study of the drug in acute coronary syndrome, defined as a heart attack or unstable angina, said Gibson.

The drug was added to t
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
3. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Phase 2a Data for MEDI-528 Presented at CHEST 2008
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
9. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
10. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based ... its new True North Conference Center. The medical community, social workers, law enforcement, ... may be more aligned in the effort to better understand and combat sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Radiation Oncology (ASTRO) has released evidence-based guidelines to ... finding that hypofractionated (HF) WBI is effective for ... are published in the International Journal of ... , Studies have shown that WBI following breast ...
... that controls the number of hematopoietic stem cells cells ... In a report in the online Early Edition of ... from Massachusetts General Hospital (MGH) and the Harvard Stem Cell ... of these blood stem cells, an advance that may improve ...
... By Jenifer Goodwin HealthDay Reporter , ... outbreak of whooping cough in decades, public health officials ... those who come into contact with infants, to make ... With the incidence of whooping cough also higher than ...
... DC Delivering timely, open, online access to the ... will significantly increase the return on the public,s investment ... Houghton at the Centre for Strategic Economic Studies at ... on Investment in Open Archiving Publicly Funded Research Outputs," ...
... Yeni H. Ycel, an ophthalmic pathologist at St. Michael,s Hospital, ... the New York Academy of Medicine. Dr. Ycel received ... the human eye that may lead to new treatments for ... assumption that the eye has no lymphatics, the channels responsible ...
... accurately detect and alleviate symptoms of delirium in persons ... the National Institute of Nursing Research. The project, ... seeks to improve nurses, assessment skills and reduce the ... Delirium and dementia have similar symptoms -- decline in ...
Cached Medicine News:Health News:ASTRO publishes whole breast irradiation guidelines 2Health News:MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment 2Health News:Spread of Whooping Cough Raises Concern 2Health News:Spread of Whooping Cough Raises Concern 3Health News:New study examines the economic returns of public access policies 2Health News:Nurses will test method for determining if it's dementia or delirium 2
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2012  Biomerix Corporation announced today that it has received ... tissue repair mesh, a novel composite mesh intended for ... for the temporary bridging of fascial defects.  This approval ... certification in many other parts of the world that ...
... 2012  Sanofi US today announced that the U. S. ... injunction against a Synvisc-One ® (hylan ... ruling allows for a restricted launch of Seikagaku,s product ... prohibits Seikagaku from selling their product below the current ...
Cached Medicine Technology:Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh 2Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product 2
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: